<DOC>
	<DOCNO>NCT02616120</DOCNO>
	<brief_summary>The purpose study examine efficacy safety SQJZ Herbal Mixtures non-motor symptom PD patient .</brief_summary>
	<brief_title>Effect SQJZ Herbal Mixtures Non-motor Symptoms Parkinson 's Disease</brief_title>
	<detailed_description>This multicentre , double-blind , placebo-controlled , parallel-group trial . Patients randomly assign via random number table either SQJZ herbal mixture placebo 2:1 ratio . Randomization stratify age gender . All participant ask maintain regular medication schedule 12-week intervention . Assessments conduct prior intervention 4-week , 8-week 12-week directly intervention . Also , long-term effect assess 24 week follow-up ( post-enrolment ) . The assessment perform blinded investigator involve randomization .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>1 . Subject idiopathic Parkinson 's disease diagnostic standard ( UKPDC ) 2 . Subject Hoehn Yahr stage score ≤4 3 . Subject male female , ≥18 year age，and≤80 year . 4 . Subject total NonMotor Symptoms Scale ( NMSS ) score ≥40 5 . If subject receive levodopa ( LDOPA ) , anticholinergic , monoamine oxidase ( MAO ) B inhibitor , amantadine , he/she must stable dose least 28 day prior Baseline Visit must maintain dose duration study 6 . Subject agree sign inform consent . 1 . Subject receive therapy antiParkinson 's disease drug ( include levodopa ( LDOPA ) , amantadine , anticholinergic , monoamine oxidase ( MAO ) B inhibitor , dopamine receptor agonists catecholOmethyltransferase inhibitor ) , guidance professional doctor , either concurrently within 28 day prior Baseline Visit . 2 . Subject receive therapy 1 follow drug , either concurrently within 28 day prior Baseline Visit : alphamethyl dopa , metoclopramide , reserpine , sibelium , neuroleptic ( except specific atypical neuroleptic : olanzapine , ziprasidone , aripiprazole , clozapine , quetiapine ) , monoamine oxidaseA ( MAOA ) inhibitor , methylphenidate , amphetamine . 3 . Subject receive central nervous system ( CNS ) therapy ( eg , sedative , hypnotic , selective serotonin reuptake inhibitor [ SSRIs ] , anxiolytic , sleepmodifying medication ) unless dose stable daily least 28 day prior Baseline Visit likely remain stable duration study 4 . Subject visual hallucination , visual hallucination happen within 1 year diagnose PD . 5 . Subject delirium。 6 . Subject Other digestive , Urological , blood system , endocrine , immune system cardiopulmonary problem view researcher . 7 . Subject Serum creatinine≥97umol/L；or alanine aminotransferase ( ALT ) ≥40U/L ; aspartate aminotransferase≥40U/L。 8 . Subject epilepsy history . 9 . Subject evidence impulse control disorder , history mental illness , thought behavior suicide . 10 . According assessment investigator , Subject n't complete study due poor compliance , drug Alcohol abuse . 11 . Subject participate clinical trial Participated past 2 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Herbal therapy</keyword>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Non-motor Symptoms</keyword>
	<keyword>Randomized control trial</keyword>
</DOC>